CRISPR Therapeutics (CRSP)
(Delayed Data from NSDQ)
$62.94 USD
+3.87 (6.55%)
Updated Sep 18, 2025 04:00 PM ET
Pre-Market: $63.02 +0.08 (0.13%) 9:06 AM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
CRSP 62.94 +3.87(6.55%)
Will CRSP be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CRSP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRSP
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2025
CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know
CRSP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Vertex Plunges Around 24% in Six Months: How to Play the Stock
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
Wall Street Analysts See CRISPR Therapeutics (CRSP) as a Buy: Should You Invest?
Other News for CRSP
Is CRSP showing upside potential? Pocket Pivot shows up after surging 6.55%
My Top Biotech Stock Picks And Portfolio Strategy For The Next 3-10 Years
CRISPR Therapeutics (CRSP) Gains on J.P. Morgan's Overweight Rating
CRISPR Therapeutics wins new Overweight rating at J.P. Morgan on pipeline prospects
CRSP forms Stochastic Sell Signal on September 17